Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials
Article Abstract:
Data for all randomized trials conducted with abciximab in ST-segment elevation myocardial infarction (STEMI) are combined. The results revealed that, when compared with the control group, adjunctive abciximab for STEMI is associated with a significant reduction in 30-day and long-term mortality in patients treated with primary angioplasty but not in those receiving fibrinolysis.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
Article Abstract:
Giving patients with coronary artery disease a stent plus the drug abciximab appears to be the most effective treatment for preventing a heart attack. A stent is a small cylindrical device that is inserted into an artery to keep it open. Abciximab is a drug that prevents the formation of blood clots. Researchers randomly assigned 2,399 patients with coronary artery disease to receive a stent only, a stent and abciximab, or balloon angioplasty plus abciximab. The lowest rate of heart attack and death occurred in the group that received a stent and abciximab.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization
- Abstracts: Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/ IIIa blockade during percutaneous coronary revascularization
- Abstracts: Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism
- Abstracts: Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections
- Abstracts: Effects of Atorvastatin of Early Recurrent Ischemic Events in Acute Coronary Syndromes: A Randomized Controlled Trial